StoneWise Takes Healthcare Track Championship at 2026 AHK Innovation Night
On June 4, the 2026 AHK Innovation Night, hosted by the German Chamber of Commerce Abroad (AHK) Greater China, successfully concluded in Suzhou. Standing out among hundreds of participating enterprises after preliminary online rounds and rigorous expert reviews, StoneWise claimed the top prize in the healthcare category. As the only AI drug R&D enterprise to win an award this year, the recognition fully demonstrates international experts’ high regard for our technological strengths and global competitiveness.
A high-profile Sino-German innovation event, AHK Innovation Night gathered over 200 business leaders, industry specialists and investment representatives from both countries to explore opportunities for industrial innovation and cross-border collaboration. Ke Mingcheng, Managing Director & Board Member for East and Central China at the German Chamber of Commerce in China, delivered an opening speech to kick off the event.
Xinhua News covered the gala and conducted exclusive interviews with the StoneWise team on site.
This achievement is built on our robust technological moat, proven industrial implementation capabilities and forward-looking global vision.
Drug discovery has evolved dramatically over decades. The industry has shifted from traditional experiment- and experience-driven R&D to Computer-Aided Drug Design (CADD), and further progressed through two stages of AI-Driven Drug Discovery (AIDD): AIDD 1.0 for single-algorithm optimization and AIDD 2.0 for data-centric development. Currently, the sector is stepping into AIDD 3.0, a new era defined by automated workflows and integrated tool collaboration powered by AI agents.
Pioneering this industry transformation, StoneWise has developed Molvortex, a full-stack intelligent agent dedicated to small-molecule drug discovery. Rooted in our self-developed 3D molecular generation platform Molvado and massive in-house datasets, Molvortex builds collaborative multi-agent workflows. It unifies fragmented AI capabilities, data and research insights to cover the full pipeline, including target pocket analysis, molecular design, result evaluation and experimental feedback.
With a well-structured multi-agent matrix, Molvortex autonomously streamlines the entire process from hit discovery and lead optimization to Pre-Candidate Compound (PCC) selection. It closely connects with wet-lab work such as chemical synthesis, activity testing and in vivo validation, working alongside researchers to iterate molecular designs and accelerate PCC development. Data accumulated across projects is fed back into the system to enable continuous optimization and form a self-evolving loop. By enabling deep integration of AI, wet-lab experiments and human expertise, Molvortex lays the foundation for next-generation AI-powered drug discovery infrastructure.
Beyond pharmaceutical R&D, the platform holds great potential for broader scientific fields. Its capabilities can be extended to small-molecule development across materials science, agriculture, medical aesthetics and more, supporting cross-industry deployment.
In real-world applications, our solutions have helped multiple partners efficiently identify novel molecular scaffolds. Our AI molecular design platform once delivered nanomolar-level active PCC within just one month. More importantly, Molvortex is able to cut the traditional early R&D cycle from 6–24 months to under 3 months, significantly lowering costs and improving the success rate of early-stage drug research.
StoneWise has assembled an interdisciplinary team combining expertise in medicinal chemistry, computational chemistry and AI. We now serve over 100 pharmaceutical firms and research institutions worldwide, with operational hubs in San Francisco, Shanghai, Beijing, Shenyang and Hong Kong, forming a global innovation network.
From leading the industry into the AI agent era and building a fully connected, self-evolving R&D system, to delivering global technological solutions and fostering ecosystem collaboration, StoneWise acts as a key bridge connecting China’s AI pharmaceutical innovation with the global industrial landscape. Moving forward, we will take this award as a new starting point to deepen Sino-German exchanges and cooperation in biomedicine. We will actively engage with high-quality industrial resources and innovation networks across Europe, drive cross-domain integration and practical deployment of cutting-edge technologies, and boost the efficiency of global drug discovery. Together with global partners, we strive to advance the life science industry to new heights.
About StoneWise
Founded in 2018, StoneWise is a global leader in AI-powered innovative drug R&D.
We have developed the industry’s first end-to-end intelligent engine for new drug design, built around medicinal chemists’ decision-making workflows. Our proprietary multimodal AI 3D molecular generation foundation model, empowered by generative AI, features high transferability and iterative capability. Combined with a library of millions of virtual compounds, our integrated computational and wet-lab solutions streamline early drug R&D.
We provide molecular generation & design, custom model training, compound screening and other products and services to hundreds of pharmaceutical companies and research institutions globally. We also advance more than ten in-house drug development pipelines, several of which have entered clinical trials.
Contact Us
Business Cooperation: bd@stonewise.cn
Customer Support: support@stonewise.cn
Investor Relations: ir@stonewise.cn
Media Inquiries: pr@stonewise.cn
Customer Support: support@stonewise.cn
Investor Relations: ir@stonewise.cn
Media Inquiries: pr@stonewise.cn
